ConductScience.org, home

Paper36924123

Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences.

Yang T and 5 others. Clin Mol Hepatol, 2023. Cited by 24 papers, by iCite.

Cite this record

ConductScience Library. Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences. Papers, record 36924123. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36924123

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences.
PubMed
Journal
Clin Mol Hepatol
PubMed
Year
2023
PubMed
Publication types
Editorial, Comment
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
2.15
iCite
Revised in PubMed
2023-07-24
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yang TTian
2Wang MDMing-Da
3Xu XFXin-Fei
4Li CChao
5Wu HHan
6Shen FFeng

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Humans
East Asian People
China
Hepatectomy

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
81972726National Natural Science Foundation of ChinaPubMed
82273074National Natural Science Foundation of ChinaPubMed
21SG36Dawn Project Foundation of ShanghaiPubMed
2022XD001Shanghai Health Academic Leader ProgramPubMed

Source PubMed

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment on36545708Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective.https://conductscience.org/library/papers/36545708

Source PubMed

Download CSV of comments and corrections

References13

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136545708Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective.Clin Mol Hepatol2023https://conductscience.org/library/papers/36545708PubMed
228634137Comparison of Patterns and Outcomes of Liver Resection for Hepatocellular Carcinoma: East vs West.Clin Gastroenterol Hepatol2017https://conductscience.org/library/papers/28634137PubMed
332707225aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.J Hepatol2020https://conductscience.org/library/papers/32707225PubMed
425722082Liver disease in China: A long way to go.Hepatology2015https://conductscience.org/library/papers/25722082PubMed
525752327Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.Liver Int2015https://conductscience.org/library/papers/25752327PubMed
630319983Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).Liver Cancer2018https://conductscience.org/library/papers/30319983PubMed
730909504Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach.Int J Mol Sci2019https://conductscience.org/library/papers/30909504PubMed
824909910Building the multidisciplinary team for management of patients with hepatocellular carcinoma.Clin Gastroenterol Hepatol2015https://conductscience.org/library/papers/24909910PubMed
929159910Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice.Hepatology2018https://conductscience.org/library/papers/29159910PubMed
1027072539Challenge of China's rural health.BMJ2016https://conductscience.org/library/papers/27072539PubMed
1136161463Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook.Liver Int2022https://conductscience.org/library/papers/36161463PubMed
1231543386Real-world role of performance status in surgical resection for hepatocellular carcinoma: A multicenter study.Eur J Surg Oncol2019https://conductscience.org/library/papers/31543386PubMed
1327761414Controversies and evidence of hepatic resection for hepatocellular carcinoma.BBA Clin2016https://conductscience.org/library/papers/27761414PubMed

Download CSV of references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
42953582Psychological Stress in Hepatocellular Carcinoma: Clinical Outcomes and Biological Mechanisms.J Hepatocell Carcinoma2026https://conductscience.org/library/papers/42953582PubMed
42757287Bibliometric Analysis of Gut Microbiota and Hepatocellular Carcinoma: Research Trends and Frontiers.J Hepatocell Carcinoma2026https://conductscience.org/library/papers/42757287PubMed
42567984Quercetin, an ingredient of Jiedu Xiaozheng Yin, alleviates hepatocellular carcinoma progression by regulating CYP1A2/PTEN/PI3K/Akt axis.In Vitro Cell Dev Biol Anim2026https://conductscience.org/library/papers/42567984PubMed
42317344Comprehensive characterization of SLC41A3 identifies it as an immune-related prognostic biomarker and therapeutic target in hepatocellular carcinoma.Front Immunol2026https://conductscience.org/library/papers/42317344PubMed
42255207SF3B4 stabilizes SREBF1 via 3'UTR binding to drive hepatocellular carcinoma progression.Front Oncol2026https://conductscience.org/library/papers/42255207PubMed
42181737ENPP2 Dysregulation Defines a Candidate Biomarker Axis Coupling Tumor-Intrinsic cAMP Signaling to Macrophage Polarization in Hepatocellular Carcinoma.Hum Mutat2026https://conductscience.org/library/papers/42181737PubMed
42068148Association Between Multi-Laboratory Parameters Pre- and Post-Treatment and Pathological Features and Their Values in Clinical Decision in Primary Hepatic Carcinoma.J Clin Lab Anal2026https://conductscience.org/library/papers/42068148PubMed
41922917Management and outcomes of patients with liver cancer in China and the United States.Chin Med J (Engl)2026https://conductscience.org/library/papers/41922917PubMed
41264215Exosomal FOSL1 From Cancer-associated Fibroblasts Drives the Progression and Pro-tumorigenic M2 Macrophage Polarization of Hepatocellular Carcinoma By Activating PLAU Transcription.Appl Biochem Biotechnol2026https://conductscience.org/library/papers/41264215PubMed
41121471Research on Anti-tumor Pharmacodynamics of Multi-functional Magnetic Lipid Polymer with Specific Targeted Transmission of siRNA and its Toxicity Evaluation.Curr Pharm Des2026https://conductscience.org/library/papers/41121471PubMed
40682115SNRPB/CCNB1 axis promotes hepatocellular carcinoma progression and cisplatin resistance through enhancing lipid metabolism reprogramming.J Exp Clin Cancer Res2025https://conductscience.org/library/papers/40682115PubMed
40636727Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma.ILIVER2024https://conductscience.org/library/papers/40636727PubMed
40330476METTL1-driven nucleotide metabolism reprograms the immune microenvironment in hepatocellular carcinoma: a multi-omics approach for prognostic biomarker discovery.Front Immunol2025https://conductscience.org/library/papers/40330476PubMed
40202169α-Fetoprotein model versus Milan criteria in predicting outcomes after hepatic resection for hepatocellular carcinoma: multicentre study.BJS Open2025https://conductscience.org/library/papers/40202169PubMed
38833082Integrated Bioinformatic Analysis Reveals the Oncogenic, Survival, and Prognostic Characteristics of TPX2 in Hepatocellular Carcinoma.Biochem Genet2025https://conductscience.org/library/papers/38833082PubMed
38831828Apolipoprotein H-based prognostic risk correlates with liver lipid metabolism disorder in patients with HBV-related hepatocellular carcinoma.Heliyon2024https://conductscience.org/library/papers/38831828PubMed
38794281Cell-Membrane-Coated Metal-Organic Framework Nanocarrier Combining Chemodynamic Therapy for the Inhibition of Hepatocellular Carcinoma Proliferation.Pharmaceutics2024https://conductscience.org/library/papers/38794281PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213NCBI Gene
PSEN15663PubTator's text mininghttps://conductscience.org/library/genes/5663NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36924123

GET https://conductscience.org/api/papers/v1/36924123/authors